AstraZeneca Boosts U.S. Investments Despite China Concerns

AstraZeneca has raised its annual sales forecast, bolstered by robust demand for its cancer and rare diseases medicines. The company plans $2 billion in U.S. investment, enhancing its research and manufacturing capabilities. Investors remain uneasy due to ongoing issues in its Chinese market.


Devdiscourse News Desk | Updated: 12-11-2024 17:25 IST | Created: 12-11-2024 16:51 IST
AstraZeneca Boosts U.S. Investments Despite China Concerns
Representative image Image Credit: Flickr

Pharmaceutical giant AstraZeneca has again raised its annual sales and profit forecast, following a strong third-quarter performance driven by high demand for its cancer and rare disease treatments.

The firm announced an additional $2 billion investment in U.S. research and development, boosting manufacturing sites in Maryland, Texas, and California, and creating 1,000 high-skilled jobs.

Despite the upbeat forecast, concerns linger over the company's Chinese market, where recent investigations have led to a significant drop in share value, reflecting investor apprehension.

(With inputs from agencies.)

Give Feedback